Business
Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris MI Cancer Seek
Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the publication of a Caris‑led study in The Oncologist demonstrating the ability of the Caris Lookback Program to proactively identify previously-profiled patients who become eligible for newly approved targeted therapies.
About this update from Caris Life Sciences, Inc.
[{"type":"text","content":"The Caris Lookback Program identified 13,293 patients potentially eligible for newly approved targeted therapies across 10 tumor types ","length":134,"tagName":"p","attribs":{}},{"type":"text","content":"IRVING, Texas, May 15, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the publication of a Caris‑led study in The Oncologist demonstrating the ability of the Caris Lookback Program to proactively identify previously-profiled patients who become eligible for newly approved targeted therapies.","length":413,"tagName":"p"},{"type":"image","alt":"Caris Life Sciences Logo (PRNewsfoto/Caris Life Sciences)","displaySize":"","headline":null,"caption":"Caris Life Sciences Logo (PRNewsfoto/Caris Life Sciences)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":359,"url":"https://media.zenfs.com/en/prnewswire.com/7e09703fc3526e7b3703f1e6a94d5ea8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/DYkfDi5YhqiUCC4hCHfZpQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTYzMw--/https://media.zenfs.com/en/prnewswire.com/7e09703fc3526e7b3703f1e6a94d5ea8","width":400,"height":359},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/xS87Ss8EcVJzBN8xSSK9jA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTU3NA--/https://media.zenfs.com/en/prnewswire.com/7e09703fc3526e7b3703f1e6a94d5ea8","width":400,"height":359}},"href":"https://mma.prnewswire.com/media/830740/Caris_Life_Sciences_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Molecular profiling reports from most labs are static, reflecting clinical knowledge only at the time of testing. As new biomarker–drug associations and therapeutic indications emerge, patients with previously identified biomarkers may miss newly approved treatment opportunities, while clinicians face increasing challenges staying current with evolving evidence.","length":364,"tagName":"p"},{"type":"text","content":"Since 2014, Caris patients have benefited from the dynamic Caris Lookback Program, which addresses limitations of static molecular profiling reports. Through this program, Caris continuously monitors new FDA approvals and guideline updates regarding biomarker‑linked therapies. When new clinical actionability is identified, Caris retrospectively reviews prior...